ESMO Congress 2012: MOLMED presented three studies on its NGR-hTNF

MolMed S.p.A. (MLM.MI) presented, at the 37th ESMO Congress, three studies on its investigational biological drug NGR-hTNF, including updated results in non-small cell lung cancer (NSCLC) patients and two retrospective analyses evaluating potential... More

MolMed S.p.A. (MLM.MI) presented, at the 37th ESMO Congress, three studies on its investigational biological drug NGR-hTNF, including updated results in non-small cell lung cancer (NSCLC) patients and two retrospective analyses evaluating potential predictors of outcome in patients enrolled in Phase I and Phase II trials. Long-term efficacy analysis confirms the potential clinical benefit in lung cancer patients with squamous cell histology Pooled efficacy analyses reveal that early drug effects strongly correlate with improved patient outcome 1 October 2012 –Long-term results (median follow-up of 20 months) presented by MolMed at the meeting validate previously presented data and confirm the potential clinical benefit of NGR-hTNF treatment in NSCLC patients with squamous cell histology and in those patients with non-squamous cell histology who were never or light former smokers. Further, retrospective analyses of patients receiving NGR-hTNF treatment indicate an interesting Less